G11778A-F84

**Figure 1\. Pedigree diagram for family G11778A\-F84\.**

![](/media/202606/20260630162751269641.png)

|  |
| --- |

# Pedigree Information

| **No.** | **Position** | **Variant** | **Family ID** | **Nationality** | **Diseases** | **Unaffected Maternal Relatives** | **Affected Maternal Relatives** | **Publication Year** | **PMID/Ref** | **Note** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | 11778 | m.11778G\>A | G11778A\-F84 | United Kingdom | LHON | ND | ND | 1995 | [7611298](https://pubmed.ncbi.nlm.nih.gov/7611298/) | Paper family 15 |

The **m.11778G\>A** variant in MT\-ND4 was reported in family G11778A\-F84 from United Kingdom with lhon. The pedigree record reported ND unaffected and ND affected maternal relatives, and the carrier table includes 4 listed carriers. Homoplasmy was reported in 0/4 listed carriers; 1/4 carriers were affected, and the main clinical manifestation among affected carriers was lhon visual loss.

# Carrier Information

| **No.** | **Position** | **Variant** | **Family ID** | **Carrier ID** | **Type (Fam/De novo/Uninf)** | **Gender (F/M)** | **Proband (Y/N)** | **Affected (Y/N)** | **Die/Alive(D/A)** | **Age** | **Blood Mutant Level** | **Muscle Mutant level** | **Urine Mutant level** | **Other Mutant level** | **Clinical Features** | **Note** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | 11778 | m.11778G\>A | G11778A\-F84 | G11778A\-F84\-II1 | Fam | F | N | N | ND | ND | \>95% | / | / | / | Healthy |  |
| 2 | 11778 | m.11778G\>A | G11778A\-F84 | G11778A\-F84\-II2 | Fam | F | N | N | ND | ND | 65% | / | / | / | Healthy |  |
| 3 | 11778 | m.11778G\>A | G11778A\-F84 | G11778A\-F84\-II3 | Fam | F | N | N | ND | ND | \>95% | / | / | / | Healthy |  |
| 4 | 11778 | m.11778G\>A | G11778A\-F84 | G11778A\-F84\-II4 | Fam | M | Y | Y | ND | ND | \>95% | / | / | / | LHON visual loss |  |

For abbreviations and other usage instructions, please see [Mitofam Info](https://mitofam.com/doc/385/).